Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eight APIs Recommended for Approval
September 4, 2006
- 1/3 of Drug-Related Accidents Are Due to Wrong Dosage: JCQHC
September 4, 2006
- RAPS to Initiate Training Program for Regulatory Affairs Professionals
September 4, 2006
- Results of Two Studies Announced by JPA
September 4, 2006
- REGULATORY NEWS IN BRIEF
August 28, 2006
- SELF-MEDICATION NEWS IN BRIEF
August 28, 2006
- Olympus Acquires Bacus to Provide Advanced Virtual Slide System
August 28, 2006
- NEW PRODUCTS Complete AminoMoist Lens Care Product: AMO
August 28, 2006
- Cook's Zenith Endograft Approved
August 28, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 28, 2006
- MEDICAL DEVICE NEWS IN BRIEF
August 28, 2006
- MPC Working Hard to Become a "Muscular" Company: President Komine
August 28, 2006
- Stem Cells Resembling ES Cells Induced from Mouse Skin Cells
August 28, 2006
- PI Forum Helps Member Companies Embark on New Businesses: Mr Ohyagi
August 28, 2006
- R&D NEWS IN BRIEF
August 28, 2006
- BUSINESS NEWS IN BRIEF
August 28, 2006
- NEW PRODUCTS
August 28, 2006
- COMMENTARY／Korosho Gets Involved to Eliminate Provisional Delivery
August 28, 2006
- Drug Development Beyond Borders -Today's Global Cooperative Clinical Trials-
August 28, 2006
- Drug Firms Should Support Job Sharing between Regional Med. Institutions: Mr Matsubara
August 28, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…